Yahoo Finance

Allergan's (AGN) Glaucoma Implant Durysta Gets FDA Approval

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Monthly Prescribing Reference

Durysta Approved for Open-Angle Glaucoma, Ocular Hypertension

The Food and Drug Administration (FDA) has approved Durysta (bimatoprost implant; Allergan) for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Healio

Early response to Durysta may lead to long-term IOP reduction

Please provide your email address to receive an email when new articles are posted on . Patients with glaucoma who displayed an early treatment response to a 10 µg bimatoprost implant and experienced ...
Mena FN

DURYSTA’S Market Potential Across The 7MM Is Set To Soar During The Study Period (2020–2034) As A Game-Changer In Ophthalmic Care | Delveinsight

(MENAFN- GlobeNewsWire - Nasdaq) The DURYSTA market potential seems strong due to the increasing prevalence of glaucoma, the need for long-term, non-adherence-dependent treatments, and its advantage ...
Healio

Biodegradable Durysta approved to lower IOP

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Nasdaq

Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in ...

- DURYSTA™ lowered intraocular pressure in patients with open-angle glaucoma or ocular hypertension by approximately 30 percent from baseline in two Phase 3 studies - - Allergan continues five ongoing ...
Medindia

Dr. James C. Loden, The First Surgeon to Implant Durysta in a Glaucoma Patient in Tennesee

NASHVILLE, Tenn., Aug. 3, 2020 /PRNewswire-PRWeb/ -- Loden Vision Centers, a leading comprehensive ophthalmology company with 5 locations across the greater Nashville and surrounding areas, has ...
Yahoo Finance

DURYSTA’s Market Potential Across the 7MM is Set to Soar During the Study Period (2020–2034) as a Game-Changer in Ophthalmic Care | DelveInsight

New York, USA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- DURYSTA’s Market Potential Across the 7MM is Set to Soar During the Study Period (2020–2034) as a Game-Changer in Ophthalmic Care | DelveInsight The ...
Business Insider

Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in ...

DUBLIN, March 5, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug ...
Yahoo Finance

Allergan's (AGN) Glaucoma Implant Durysta Gets FDA Approval

Allergan plc AGN announced that FDA has approved its new drug application seeking approval of biodegradable implant bimatoprost to reduce intraocular pressure (IOP) in patients with open-angle ...
Nasdaq

Allergan's (AGN) Glaucoma Implant Durysta Gets FDA Approval

Allergan plc AGN announced that FDA has approved its new drug application seeking approval of biodegradable implant bimatoprost to reduce intraocular pressure (IOP) in patients with open-angle ...